8-K: Aveanna Healthcare Soars in Q3, Boosts 2025 Outlook

Aveanna Healthcare Holdings Inc. reported strong third-quarter 2025 financial results, including significant revenue and Adjusted EBITDA growth, and raised its full-year 2025 guidance.

Summary

• Third-quarter 2025 revenue increased by 22.2% to $621.9 million, up from $509.0 million in the prior year period.
• The company achieved a net income of $14.1 million in Q3 2025, a significant turnaround from a net loss of $42.8 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 grew by 67.5% to $80.1 million, compared to $47.8 million in Q3 2024.
• For the nine-month period ended September 27, 2025, revenue increased by 17.7% to $1,770.7 million, and Adjusted EBITDA rose by 83.7% to $235.9 million.
• Full-year 2025 revenue guidance was increased to greater than $2.375 billion, up from the previous guidance of greater than $2.3 billion.
• Full-year 2025 Adjusted EBITDA guidance was raised to greater than $300 million, an increase from the prior guidance of greater than $270 million.
• A successful debt refinancing was completed on September 17, 2025, which included terminating the $415.0 million Second Lien Credit Agreement and extending maturity dates for credit facilities.

Sentiment

Score: 9

Explanation: The company demonstrated exceptional financial performance in Q3 2025, achieving significant revenue and Adjusted EBITDA growth, a strong turnaround to net income, and substantially raised its full-year guidance. The successful debt refinancing further strengthens its financial position and operational flexibility.

Positives

• Third-quarter 2025 revenue increased by 22.2% to $621.9 million.
• Net income for Q3 2025 was $14.1 million, a substantial improvement from a net loss of $42.8 million in Q3 2024.
• Adjusted EBITDA for Q3 2025 surged by 67.5% to $80.1 million.
• Net income per diluted share for Q3 2025 was $0.06, compared to a net loss per diluted share of $(0.22) in Q3 2024.
• Adjusted net income per diluted share for Q3 2025 increased to $0.15 from $0.02 in Q3 2024.
• Gross margin improved to 32.6% of revenue in Q3 2025 from 31.4% in Q3 2024.
• PDS segment revenue increased by $104.9 million and HHH segment revenue increased by $8.3 million in Q3 2025.
• Nine-month period revenue increased by 17.7% to $1,770.7 million.
• Nine-month period net income was $46.3 million, compared to a net loss of $40.1 million in the prior year.
• Nine-month period Adjusted EBITDA increased by 83.7% to $235.9 million.
• Net cash provided by operating activities for the nine-month period was $76.1 million, up from $19.2 million in the prior year.
• Free cash flow for the nine-month period was $86.2 million.
• Full-year 2025 revenue guidance was raised to greater than $2.375 billion.
• Full-year 2025 Adjusted EBITDA guidance was raised to greater than $300 million.
• Successful debt refinancing completed, expanding revolving credit facility to $250.0 million and extending maturity dates to September 17, 2030, and September 17, 2032, for the revolving credit facility and 2025 Term Loans, respectively.
• Integration of Thrive Skilled Pediatric Care is on track to be completed by the end of the year.

Negatives

• MS segment revenue decreased by $0.2 million in Q3 2025 compared to Q3 2024.
• Corporate expenses increased by 63.0% to $52.0 million in Q3 2025 compared to $31.894 million in Q3 2024.

Risks

• Intense competition among home health, hospice, and durable medical equipment companies.
• Ability to maintain relationships with existing patient referral sources.
• Ability to have services funded from third-party payers, including Medicare, Medicaid, and private health insurance companies, potentially impacted by changes to Medicaid under the One Big Beautiful Bill Act.
• Changes to Medicare or Medicaid rates or methods governing payments, and the implementation of alternative payment models, including Medicare Advantage, Managed Care Organization, and managed Medicaid.
• Downward pressure on reimbursement resulting from further proliferation of Medicare Advantage plans.
• Limited ability to control reimbursement rates received for services.
• Delays in collection or non-collection of patient accounts receivable, particularly during business integration or system transitions.
• Impact of healthcare reform and other regulations, including proposed rules for the home health prospective payment system by Centers for Medicare & Medicaid Services.
• Changes in the case-mix of patients, as well as payer mix and payment methodologies.
• Potential reduction in net reimbursement if value-based care programs are not effectively implemented.
• Material adverse effects on business, financial condition, and results of operations by public health emergencies, such as a pandemic or other infectious disease outbreak.
• Shortages in qualified employees and management, and competition for qualified personnel.
• Failure to maintain the security and functionality of information systems or to defend against or prevent cybersecurity attacks or breaches.
• Substantial indebtedness, which increases vulnerability to general adverse economic and industry conditions and may limit the ability to pursue strategic alternatives.
• Ability to identify, obtain financing for, acquire, and integrate strategic and accretive businesses or assets.
• Risks related to legal proceedings, claims, and governmental inquiries, including a U.S. Department of Justice, Antitrust Division's grand jury subpoena related to nurse wages and hiring activities.

Future Outlook

The company has raised its full-year 2025 guidance, now expecting revenue to be greater than $2.375 billion (up from greater than $2.3 billion) and Adjusted EBITDA to be greater than $300 million (up from greater than $270 million). This revised outlook reflects sustained momentum across its business divisions and confidence in continued operational excellence.

Management Comments

• Jeff Shaner, CEO, stated, "Our third quarter results reflect the strength and momentum in all three operating divisions as we continue year three of our Strategic Transformation."
• Shaner highlighted, "The quarter was highlighted by revenue and adjusted EBITDA growth of 22.2% and 67.5%, respectively, when compared to the prior year period."
• Shaner also noted, "The integration of Thrive Skilled Pediatric Care is on track to be completed by the end of the year."
• Matt Buckhalter, CFO, commented, "Our third-quarter results are highlighted by revenue and Adjusted EBITDA growth of 22.2% and 67.5%, respectively, compared to the prior year period."
• Buckhalter added, "Our successful debt refinancing completed during the third quarter reflects the strength of our operating performance and proven value of our national home care platform."
• Buckhalter concluded, "Based on our performance and the opportunities ahead, we are pleased to raise our full-year 2025 guidance to revenue of greater than $2.375 billion and Adjusted EBITDA of greater than $300 million."

Industry Context

Aveanna Healthcare operates as a leading, diversified home care platform, focusing on medically complex, high-cost patient populations. The strong Q3 results and increased guidance suggest that the company is effectively navigating the evolving healthcare landscape, leveraging its national footprint to deliver cost-effective and high-quality home care. This performance aligns with the broader trend of increasing demand for in-home healthcare services as a lower-cost alternative to traditional hospitalization, providing significant value to payor and government partners.

Legal Proceedings

• The company is incurring legal and forensic costs, as well as settlements, associated with resolving legal matters arising during or as a result of acquisition-related activities.
• This primarily includes costs related to complying with the U.S. Department of Justice, Antitrust Division's grand jury subpoena regarding nurse wages and hiring activities in certain markets, in connection with a terminated transaction.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, return to profitability, increased guidance, and improved capital structure, likely leading to increased share price.
• Employees: Continued focus on operational excellence and delivering strong clinical outcomes, but also risks related to shortages of qualified personnel and competition for talent.
• Customers/Patients: Continued delivery of high-quality, cost-effective home care services for medically complex populations.
• Payors/Government Partners: Value proposition of cost-effective and high-quality home care is reinforced, but risks exist from changes in reimbursement rates and regulatory policies.
• Creditors: Improved financial health and successful debt refinancing enhance the company's credit profile and extend debt maturities.

Next Steps

• Completion of the integration of Thrive Skilled Pediatric Care by the end of 2025.

Key Dates

Recommendation

The company's third-quarter results significantly exceeded prior-year performance, marked by a substantial increase in revenue and Adjusted EBITDA, and a return to net profitability from a loss. The upward revision of full-year 2025 guidance for both revenue and Adjusted EBITDA signals strong operational momentum and management confidence. Furthermore, the successful debt refinancing improves the company's capital structure and extends maturities, enhancing financial stability. These factors collectively indicate robust underlying business health and strong future prospects, making it an attractive investment.

Keywords

Home care, Healthcare services, Pediatric care, Adult care, Home health, Hospice, Financial results, Q3 2025, Earnings, Guidance, Adjusted EBITDA, Debt refinancing, AVAH, NASDAQ